Wednesday, 19 August 2026
Europe is preparing for a major change in how health information can be accessed and reused, creating a regulated cross-border framework that could increase the strategic importance of medical datasets while supporting investment in artificial intelligence, pharmaceuticals, diagnostics and digital healthcare. The European Health Data Space, or EHDS, entered into force on 26 March 2025 and is the EU’s first common data space dedicated to a specific sector. Its objectives extend beyond allowing patients and healthcare professionals to exchange medical information more easily between countries. The system will also establish a framework through which health data can be reused for approved research, innovation, regulatory and public-policy purposes.
The implications could be substantial for Europe’s life sciences industry. Pharmaceutical companies, biotechnology businesses, universities, hospitals and technology companies increasingly depend on large and diverse datasets to develop medicines, diagnostics and digital health products. Artificial intelligence is accelerating that requirement because the performance of many healthcare AI systems depends heavily on the quantity, diversity and quality of the information available for training and testing.
Europe already possesses enormous quantities of health information, but much of it sits within separate national healthcare systems, hospitals, laboratories, research institutions and incompatible digital platforms. The commercial and scientific challenge has therefore been less about whether the data exists and more about whether sufficiently large and useful datasets can legally and technically be accessed. The EHDS is intended to reduce some of that fragmentation. Researchers will eventually have a clearer system for identifying available datasets and applying to use them across Europe, potentially making it easier to undertake research involving populations and medical information from multiple countries rather than negotiating access separately with individual institutions.
However, the new framework should not be interpreted as opening European patient information freely to commercial organisations. Access for secondary purposes will be controlled by designated health data access bodies, with applicants required to demonstrate an authorised purpose and obtain permission. Processing will take place within secure environments, and personal information cannot simply be downloaded and transferred into corporate databases.
Where anonymised information is sufficient, applicants will receive anonymised data. Access to pseudonymised information will be possible where anonymisation would prevent the legitimate purpose from being achieved, but attempts to identify the individuals behind that information will be prohibited. People will also generally have the ability to opt out of secondary use, subject to limited public-interest exceptions and safeguards.
There are also clear restrictions on how information obtained through the system can be used. The framework prohibits applications including advertising and marketing and using health information to make decisions detrimental to particular individuals. This distinction is important because the economic potential of the EHDS depends partly on maintaining public confidence that greater availability for medical research does not become unrestricted commercial exploitation of patient information.
Implementation will consequently be gradual rather than immediate. The European Commission is expected to adopt important implementing measures by March 2027. The main secondary-use provisions covering most categories, including information from electronic health records, are scheduled to apply from March 2029. Remaining categories, including genomic data, follow from March 2031. Third countries and international organisations will be able to seek participation in the HealthData@EU infrastructure from 2035.
The lengthy implementation period provides businesses and research institutions with time to reconsider an increasingly important question: who controls the economic value created from health data? Historically, collaboration agreements between pharmaceutical companies, universities, hospitals and research organisations have concentrated heavily on conventional intellectual property. Negotiations typically addressed ownership of inventions, patents, licensing arrangements and the distribution of revenue from successful products.
Artificial intelligence is beginning to alter that balance. A dataset generated during one research programme may subsequently have value far beyond the original project. It could potentially contribute to another drug-development programme, assist in identifying biomarkers, support diagnostic research or be used to train and validate an algorithm. The value may therefore lie not only in the intellectual property produced during the original collaboration but also in the continuing ability to access and use the underlying information.
This creates potentially complicated commercial questions. A hospital might provide patient information, a university could contribute medical research, and a technology company could provide computing infrastructure and AI expertise. The resulting model, algorithm or dataset may then become commercially valuable in ways that were difficult to anticipate when the original collaboration was established.
Agreements drafted before AI became a major component of medical research may not clearly determine who can use information for model training, whether derived datasets can be commercialised, who controls trained models or how value created through subsequent applications should be distributed. This does not mean existing agreements automatically need to be renegotiated because of the EHDS. It does mean that data access, permitted uses, governance, derived information and AI outputs are likely to become considerably more important during future negotiations.
The changes are occurring alongside a broader attempt to improve Europe’s position in data-driven healthcare. Regulators are considering not only privacy but also whether Europe’s legal environment allows technologies including AI, genomics, biotechnology, synthetic data and advanced digital healthcare applications to develop effectively. The challenge is to create sufficient access to information for innovation without weakening protections surrounding highly sensitive medical data.
There could eventually be implications for physical investment as well. The EHDS itself does not automatically create demand for laboratories, hospitals or data centres. However, making health information more usable for research could strengthen the wider ecosystem supporting pharmaceutical R&D, biotechnology, medical technology and healthcare AI.
Processing sensitive medical information at scale requires computing capacity as well as sophisticated cybersecurity, storage and data-management systems. As AI becomes more deeply integrated into life sciences, the relationship between physical research infrastructure and digital infrastructure is therefore likely to become increasingly important. Laboratories generate biological and clinical information, hospitals generate medical records and imaging data, and computing infrastructure processes that information into research results, predictive models and potential treatments.
For property and infrastructure investors, this does not yet translate into a measurable EHDS-driven real estate market. It does, however, reinforce the longer-term convergence between life sciences real estate, healthcare infrastructure and high-security computing capacity. Research clusters containing universities, hospitals, laboratories, pharmaceutical businesses and technology companies could be particularly well positioned. Their competitive advantage increasingly depends not simply on providing laboratory space but on connecting researchers with computing resources, clinical expertise, data infrastructure and specialist talent.
The more fundamental change may be how health information itself is valued. For decades, pharmaceutical and biotechnology investment has largely been organised around intellectual property created through scientific research. AI is adding another layer in which access to sufficiently large, reliable and legally usable datasets can itself become a competitive advantage.
Europe’s challenge is to unlock some of that value without weakening the privacy protections surrounding highly sensitive medical information. The EHDS attempts to resolve that tension through controlled access rather than unrestricted data circulation. If implementation works as intended, researchers and companies should eventually be able to identify and use European health datasets more efficiently while patients retain stronger rights over their information. If the system becomes excessively complicated, costly or fragmented between national authorities, some of the intended innovation benefits could prove harder to realise.
The next several years will therefore be crucial. Member states must establish the necessary governance and technical infrastructure, organisations holding health information will have to prepare for new responsibilities, and businesses will need to reconsider how data rights are treated within research and commercial partnerships.
For Europe’s life sciences sector, the significance extends beyond regulatory compliance. As medical innovation becomes increasingly dependent on the combination of biological science, artificial intelligence and large-scale computing, access to high-quality data is becoming part of the infrastructure required to compete.
The EHDS is an attempt to build that infrastructure at European scale. Its success will ultimately be measured not simply by how much information becomes technically accessible, but by whether Europe can convert its vast health-data resources into better research, stronger life sciences innovation and new investment while retaining the trust of the people whose medical information makes that progress possible.
Source: CMS and CIJ.World Research & Analysis Team
